Throughout the report, steps that might be taken to fill
the
gaps in understanding both
the
potential harms and benefits of marijuana and cannabinoid use are identified. Those
steps include identifying knowledge gaps, promising research directions, and potential therapies based on scientific advances in cannabinoid biology.
Chapter 2 reviews basic cannabinoid biology and provides a foundation to understand
the
medical value of marijuana or its constituent cannabinoids. In consideration of the physician's first rule, "first, do no harm,"
the potential harms attributed to the medical use of marijuana are reviewed before the potential medical benefits. Chapter 3 reviews the
risks posed by marijuana use, with emphasis on medical use.
Chapter 4 analyzes the most credible clinical data relevant to the medical use of
marijuana. It
reviews what is known about the physiological mechanisms underlying
particular conditions (for example, chronic pain, vomiting, anorexia, and muscle
spasticity), what is known about the cellular actions of cannabinoids, and the levels of
proof needed to show that
marijuana is an effective treatment for specific symptoms. It does not analyze the historical literature; history is informative in enumerating uses of
marijuana, but it does not provide the sort of information needed for a scientifically sound evaluation of the efficacy and safety of marijuana for clinical use. Because
marijuana is advocated primarily as affording relief from the symptoms of disease rather
than as a cure, this chapter is organized largely by symptoms as opposed to disease
categories. Finally, chapter 4 compares the conclusions of this report with those of other recent reports on the medical use of marijuana.
Chapter 5 describes the process of and analyzes
the
prospects for cannabinoid drug
development.
0 commentaires